The sponsor of a pharmaceutical LSD formulation announces positive topline results in a Phase 3 depression trial
The Phase 3 Emerge trial of DT120, a pharmaceutical LSD formulation, in adults with major depressive disorder reached its primary completion date on 20 May 2026, and the sponsor, Definium Therapeutics, announced positive topline results on 22 June 2026. No results have been posted to the trial registry and nothing has been peer reviewed, so the size of the effect and any comparison with other antidepressants cannot be checked. The trial enrolled people with major depression, not healthy adults.
Definium Therapeutics press release, 22 June 2026 · ClinicalTrials.gov NCT06941844 · reliability: low (grade 3), a company announcement of unpublished data.
A 2026 meta-analysis finds a standard psilocybin dose clearly beats control for depression
Pooling six randomized controlled trials, a meta-analysis found a standard psilocybin dose superior to control for major depression, with higher response and remission rates sustained for weeks, and lower dropout than control. A low dose showed no such advantage. It's some of the firmest evidence yet that dose and context matter.
Kishi T et al., Journal of Affective Disorders, 2026, PMID 41876058, DOI 10.1016/j.jad.2026.121675 · meta-analysis of 6 RCTs · reliability: strong (peer-reviewed).
The FDA says it issued national priority vouchers to three psychedelic programs
At its public hearing on 14 September 2026, the FDA said that in April it issued national priority vouchers to three companies, studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for post-traumatic stress disorder. A voucher is meant to shorten the agency's review. It does not approve a drug or change its legal schedule, and these substances remain federally controlled.
FDA opening remarks, public hearing on psychedelic drugs, 14 September 2026, docket FDA-2026-N-7542, hearing notice, Federal Register document 2026-14155 · reliability: official statement.
A 12-month psilocybin follow-up shows lasting improvement, but cannot show the drug caused it
A 12-month follow-up of the German EPIsoDE trial in treatment-resistant depression found depression scores still about 7.7 points below baseline on the HAMD17 scale a year after treatment. Two cautions belong with it. The parent randomized trial missed its primary endpoint: response at week 6 was 17.0 percent in the higher-dose psilocybin group against 10.6 percent in the active placebo group, with a confidence interval for the odds ratio (0.53 to 6.23) that included no effect. That trial also reported more suicidal ideation on dosing days in the higher-dose group and two serious adverse reactions. The follow-up was naturalistic and found no significant differences between the randomized groups, so it cannot separate the drug from the psychotherapy and the passage of time. Participants who restarted antidepressant medication had higher scores. This was a clinical population, not healthy adults.
Mertens LJ et al., follow-up, Psychotherapy and Psychosomatics, 2026, PMID 42201843, DOI 10.1159/000552272. Parent trial: Mertens LJ et al., JAMA Psychiatry, 2026, PMID 41848690, DOI 10.1001/jamapsychiatry.2026.0132 · reliability: moderate for persistence of improvement, weak for attribution to psilocybin.
The honest caveat we attach to all of it
Most of this research asks whether psychedelics can treat illness. Metanoia's question is different, whether, used carefully, they can help healthy people thrive, and there the evidence is genuinely promising but far less settled. We report the field as it is: the strong results and the thin ones, side by side. None of this is medical or legal advice, and these substances remain controlled in most places.